The Early Diagnosis of Gestational Diabetes Mellitus Study
Not Applicable
- Conditions
- Gestational Diabetes Mellitus
- Registration Number
- NCT02740283
- Lead Sponsor
- First Affiliated Hospital, Sun Yat-Sen University
- Brief Summary
The main purpose of the study is to evaluate an OGTT at 18 to 20 gestational weeks as an early diagnosis method of GDM in low risk pregnant women. By investigating maternal and neonatal outcomes that are associated with the early OGTT and regular OGTT results, the study will provide a evidence for the most appropriate time to perform an OGTT in pregnant women.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- Female
- Target Recruitment
- 300
Inclusion Criteria
- Singleton pregnant women will be invited to participate in this study if they are between 18 and 40 years of age, and have had their first prenatal visit in our center before 18 weeks 0 days of gestation.
Exclusion Criteria
- Previous history of GDM or preexisting DM
- Family history of diabetes mellitus (first degree relative with diabetes or a sister with GDM)
- Body mass index>30 kg/m2
- Previous macrosomia (baby with birth weight >4,000 g) or a history of stillbirth
- Polycystic ovary syndrome
- Medications: corticosteroids, antipsychotics
- Participant not willing to take OGTT twice (at 18-20 gestational weeks and 24-28 gestational weeks), or not willing to have a series of prenatal care visits and deliver in our center.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method Rate of GDM diagnosed in 18-20 gestational week. up to 12 months
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie early OGTT detection of GDM in low-risk pregnancies?
How does early OGTT compare to standard 24-28 week screening in predicting maternal and neonatal outcomes?
Which biomarkers correlate with GDM progression in low-risk women undergoing early OGTT?
What adverse events are associated with early dietary interventions in GDM management?
Are combination therapies of glycemic monitoring and dietary guides more effective than standard care for early GDM diagnosis?